ClinicalTrials.gg
TerminatedNCT04746924Updated May 12, 2026Results posted

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

A Phase 3 interventional study of Tislelizumab and Ociperlimab in Non-small Cell Lung Cancer and NSCLC, sponsored by BeiGene. Terminated at 218 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by BeiGene · Phase 3, Interventional, and Treatment

Why this study was terminated
This decision was conducted by the sponsor based on lack of efficacy and not driven by safety concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
669
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 41 studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung — 20 open to participants now, 22 under way, 2 of them phase 3. tislelizumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
2nd of 41
669 · median 39
Started
2021
with 4 others
Phase 3
9 of 41
none open now
Registered
9th of 41
by date
Lead sponsor
10 of 41
BeiGene

Among the 41 studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung, this one is the 2nd largest by enrollment, is one of 5 that started in 2021, is one of 9 in phase 3, and was the 9th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

20 of the 41 studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About tislelizumab

tislelizumab: first FDA approval 2024 (TEVIMBRA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of ociperlimab + tislelizumab compared with that of pembrolizumab in adults with high levels of programmed cell death ligand-1 (PD-L1), locally advanced/recurrent or untreated metastatic non-small cell lung cancer (NSCLC).

03

Conditions studied

  • Non-small Cell Lung Cancer
  • NSCLC

Keywords

  • Locally Advanced
  • Unresectable
  • Metastatic
  • Tislelizumab
  • BGB-A317
  • Ociperlimab
  • BGB-A1217
  • Pembrolizumab
  • Anti-TIGIT
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. or cytologically documented locally advanced or recurrent non-small cell lung cancer (NSCLC) that is not eligible for curative surgery and/or definitive radiotherapy with or without chemoradiotherapy, or -nonsquamous or squamous NSCLC.
  2. No prior systemic treatment for metastatic NSCLC.
  3. Agreement to provide or fresh biopsy (if archival tissue is not available).
  4. Tumors with expressed in ≥ 50% tumor cells.
  5. At least 1 as defined per (RECIST) v1.1.
  6. (ECOG) Performance Status ≤ 1.

Key Exclusion Criteria:

  1. Known mutations in the epidermal growth factor receptor (EGFR) gene, anaplastic lymphoma kinase (ALK) fusion oncogene, BRAF V600E, or ROS1.
  2. Prior therapy with an anti-programmed cell death protein (anti-PD)-1, anti-PD-ligand (L)-1, anti-PD-ligand-2, anti-T-cell immunoglobulin and ITIM (anti-TIGIT) domain, or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways.
  3. Active or uncontrolled, untreated .
  4. Active diseases or history of autoimmune diseases that may relapse.

Note: Other protocol defined Inclusion/Exclusion criteria may apply

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
669 participants (actual)

Study arms

  • Experimental
    Arm A: Ociperlimab plus Tislelizumab

    Participants received ociperlimab 900 mg and tislelizumab 200 mg intravenously every 3 weeks. Treatment continued until lack of benefit, unacceptable toxicity, or withdrawal for other reasons.

    Drug: Tislelizumab · Drug: Ociperlimab

  • Active comparator
    Arm B: Pembrolizumab plus Placebo

    Participants received pembrolizumab 200 mg and placebo intravenously every 3 weeks. Treatment continued until lack of benefit, unacceptable toxicity, or withdrawal for other reasons.

    Drug: Pembrolizumab · Drug: Placebo

  • Placebo comparator
    Arm C: Tislelizumab plus Placebo

    Participants received tislelizumab 200 mg and placebo intravenously every 3 weeks. Treatment continued until lack of benefit, unacceptable toxicity, or withdrawal for other reasons.

    Drug: Tislelizumab · Drug: Placebo

  • Experimental
    Safety Run-In Substudy

    Japanese participants received ociperlimab 900 mg and tislelizumab 200 mg every 3 weeks. Treatment continued until lack of benefit, unacceptable toxicity, or withdrawal for other reasons.

    Drug: Tislelizumab · Drug: Ociperlimab

Interventions

  • Tislelizumab is a monoclonal antibody formulated for intravenous injection.

    Also known as: BGB-A317

  • Ociperlimab is a monoclonal antibody formulated for intravenous injection.

    Also known as: BGB-A1217

  • Pembrolizumab is a monoclonal antibody formulated for intravenous injection.

    Also known as: KEYTRUDA

  • DrugPlacebo

    Placebo infusions will consist of a sterile, normal saline solution.

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS) in Arms A and B

    OS is defined as the time from the date of randomization to the date of death due to any cause. Median OS was estimated using the Kaplan-Meier method. OS was a pre-specified primary endpoint for Arms A and B only.

    Time frame: From randomization until the end of the study. Maximum time on study was 45.0 months

  2. Safety Run-In Substudy: Number of Participants Experiencing Adverse Events (AEs)

    The severity of AEs was determined according to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v5.0). AEs were graded on a scale of Grade 1 to Grade 5, with Grade 1 being the least severe and Grade 5 being the most severe. An AE is defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a study drug, whether considered related to study drug or not. A serious adverse event (SAE) is any untoward medical occurrence that, at any dose resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect, was considered a significant medical AE by the investigator based on medical judgement.

    Time frame: From first dose of study drug to 30 days after last dose. Maximum treatment duration was 12.45 months.

  3. Safety Run-In Substudy: Serum Concentration of Ociperlimab

    Time frame: Cycle 1 Day 1 (C1D1) Postdose (30 minutes after end of infusion), 24 and 72 Hours Postdose; C1D8; C1D15; C2D1 Predose and Postdose; C5D1 Predose; C5D1 Postdose; C5D8; C5D15; C6D1 Predose and Postdose; C9D1 Predose; C13D1 Predose; End of Treatment.

Secondary outcomes

  1. Progression-free Survival (PFS) for Arm A Versus Arm B As Assessed By the Investigator

    PFS is defined as the time from the date of randomization to the date of the first objectively documented tumor progression per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, or death, whichever occurs first. Median PFS was estimated using the Kaplan-Meier method. PFS was a pre-specified secondary endpoint for Arms A and B only. Progressive disease is defined as at least a 20% increase in the sum of diameters of target lesions, unequivocal progression of existing non-target lesions, or new lesions.

    Time frame: Up to 45.0 months

  2. Progression-free Survival (PFS) for Safety Run-In Substudy As Assessed By the Investigator

    PFS is defined as the time from the date of randomization to the date of the first objectively documented tumor progression per RECIST v1.1, or death, whichever occurs first. Median PFS was estimated using the Kaplan-Meier method.

    Time frame: Up to 38.9 months

  3. Overall Response Rate (ORR) for Arm A Versus Arm B As Assessed By the Investigator

    ORR is defined as the percentage of participants with a documented, confirmed complete response or partial response per RECIST v1.1. ORR was a pre-specified secondary endpoint for Arms A and B only. Complete response is defined as disappearance of all target lesions, disappearance of all nontarget lesions and normalization of tumor marker level, and no new lesions. Partial response is defined as at least a 30% decrease in the sum of diameters of target lesions, no unequivocal progression of non-target lesions, and no new lesions.

    Time frame: Response was assessed every 9 weeks from randomization for the first 52 weeks and then every 12 weeks thereafter, up to 45.0 months

  4. Overall Response Rate (ORR) for Safety Run-In Substudy As Assessed By the Investigator

    ORR is defined as the percentage of participants with a documented, confirmed complete response or partial response per RECIST v1.1.

    Time frame: Response was assessed every 9 weeks from randomization for the first 52 weeks and then every 12 weeks thereafter, up to 38.9 months

  5. Duration Of Response (DOR) for Arm A Versus Arm B As Assessed By the Investigator

    DOR is defined as the time from the first determination of an objective response per RECIST v1.1 until the first documentation of progression or death, whichever occurs first. Median DOR was estimated using the Kaplan-Meier method. DOR was a pre-specified secondary endpoint for Arms A and B only.

    Time frame: Up to 45.0 months

  6. Duration Of Response (DOR) for Safety Run-In Substudy As Assessed By the Investigator

    DOR is defined as the time from the first determination of an objective response per RECIST v1.1 until the first documentation of progression or death, whichever occurs first. Median DOR was estimated using the Kaplan-Meier method.

    Time frame: Up to 38.9 months

  7. Change From Baseline in Global Health Status (GHS)/Quality of Life (QoL), Physical Functioning, and Pain Scores: European Organization For Research And Treatment Of Cancer Quality Of Life Questionnaire Core 30 (EORTC QLQ-C30) in Arms A and B

    The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical, role, emotional, cognitive, and social functioning), 1 GHS scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 = Not at all (best) and 4 = Very Much (worst) and 2 global health QoL questions answered on a 7-point scale where 1 = Very poor and 7 = Excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. Higher scores in GHS and functional scales indicate better quality of life. Lower scores in symptom scales indicate better quality of life. Included in this outcome measure were evaluation of GHS/QoL, physical functioning, and fatigue. This was a pre-specified secondary endpoint for Arms A and B only.

    Time frame: Baseline to Cycle 5 and Cycle 7, each cycle was 3 weeks

  8. Change From Baseline in EORTC Lung Cancer Module Quality of Life Questionnaire Lung Cancer 13 (QLQ-LC13) Index Score, Dyspnea, Coughing, Hemoptysis, Pain in Chest, Pain in Arms/Shoulders, and Peripheral Neuropathy Scores in Arms A and B

    The EORTC QLQ-LC13 is the lung cancer module of the QLQ-C30 and measures lung cancer-specific disease and treatment symptoms. It includes 13 questions about specific symptoms in which participants respond based on a 4-point scale, where 1 is "not at all" and 4 is "very much". Raw scores are transformed into a 0 to 100 scale via linear transformation. The symptom index scale was calculated by taking the mean of all symptom scale scores, and ranges from 0 to 100. Lower scores indicate an improvement in symptoms. This was a pre-specified secondary endpoint for Arms A and B only.

    Time frame: Baseline to Cycle 5 and Cycle 7, each cycle was 3 weeks

  9. Change From Baseline in European Quality of Life-5 Level- 5 Dimension (EQ-5D-5L) Visual Analog Scale in Arms A and B

    The EQ-5D-5L comprises a descriptive module that includes five dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) and a Visual Analog Scale (VAS). The VAS records a participant's self-rated health on a vertical scale from 0 to 100, where 0 is 'the worst health you can imagine' and 100 is 'the best health you can imagine'. A higher score indicates better health outcomes. This was a pre-specified secondary endpoint for Arms A and B only.

    Time frame: Baseline to Cycle 5 and Cycle 7, each cycle was 3 weeks

  10. Time To Deterioration (TTD) in Arms A and B Based on QLQ-LC13 Index Score, Cough, Chest Pain, Dyspnea, Hemoptysis, Arm or Shoulder Pain, and Peripheral Neuropathy

    TTD is defined as the time from randomization to the first occurrence of worsening scores of ≥ 10 points from baseline for 2 consecutive assessments or 1 assessment followed by death from any cause. TTD was estimated using the Kaplan-Meier method. TTD was a pre-specified secondary endpoint for Arms A and B only.

    Time frame: Up to 45.0 months

  11. Time To Deterioration (TTD) in Arms A and B Based on QLQ-C30 GHS/QoL Score, Physical Functioning, and Fatigue

    TTD is defined as the time from randomization to the first occurrence of worsening scores of ≥10 points from baseline for 2 consecutive assessments or 1 assessment followed by death from any cause. TTD was estimated using the Kaplan-Meier method. TTD was a pre-specified secondary endpoint for Arms A and B only.

    Time frame: Up to 45.0 months

  12. Number Of Participants Experiencing Adverse Events (AEs) in Arm A

    The severity of AEs was determined according to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v5.0). AEs were graded on a scale of Grade 1 to Grade 5, with Grade 1 being the least severe and Grade 5 being the most severe. An AE is defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a study drug, whether considered related to study drug or not. An SAE is any untoward medical occurrence that, at any dose resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect, was considered a significant medical AE by the investigator based on medical judgement. This was a pre-specified secondary endpoint for Arm A only.

    Time frame: From first dose of study drug up to 30 days after last dose (or 90 days for immune-mediated AEs); maximum treatment duration was 45.0 months

  13. Safety Run-In Substudy: Participants With Anti-Drug Antibodies

    Time frame: Up to 38.9 months

07

Results

Posted May 12, 2026

Participant flow

Participants were enrolled at 200 centers in 20 countries globally. A safety run-in substudy was conducted to evaluate preliminary safety and tolerability in Japanese participants before Japanese participants were randomized into the study.

Participant flow — Overall Study
MilestoneArm A: Ociperlimab Plus TislelizumabArm B: Pembrolizumab Plus PlaceboArm C: Tislelizumab Plus PlaceboSafety Run-In Substudy
Started287287887
Received treatment286287877
Completed0000
Not completed287287887
Withdrew: Death127134435
Withdrew: Study closed by sponsor141136402
Withdrew: Drug withdrawal by participant141620
Withdrew: Physician decision3010
Withdrew: Lost to follow-up2120

Outcome measures

PrimaryOverall Survival (OS) in Arms A and B

OS is defined as the time from the date of randomization to the date of death due to any cause. Median OS was estimated using the Kaplan-Meier method. OS was a pre-specified primary endpoint for Arms A and B only.

Time frame:
From randomization until the end of the study. Maximum time on study was 45.0 months
Reported as:
Median · months
Overall Survival (OS) in Arms A and B
monthsArm A: Ociperlimab Plus TislelizumabArm B: Pembrolizumab Plus Placebo
Overall Survival (OS) in Arms A and B31.9 (25.7 to NA)29.4 (25.8 to 35.0)
Statistical analysis
  • Arm A: Ociperlimab Plus Tislelizumab vs Arm B: Pembrolizumab Plus Placebo · Log Rank · p = 0.4050 · Hazard ratio (hr): 0.97 · 95% CI 0.76 to 1.23Hazard ratio was estimated using a Cox regression model stratified by regions of enrollment (Asia versus non-Asia) and histology (squamous versus non-squamous) with Arm B as the reference group.
PrimarySafety Run-In Substudy: Number of Participants Experiencing Adverse Events (AEs)

The severity of AEs was determined according to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v5.0). AEs were graded on a scale of Grade 1 to Grade 5, with Grade 1 being the least severe and Grade 5 being the most severe. An AE is defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a study drug, whether considered related to study drug or not. A serious adverse event (SAE) is any untoward medical occurrence that, at any dose resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect, was considered a significant medical AE by the investigator based on medical judgement.

Time frame:
From first dose of study drug to 30 days after last dose. Maximum treatment duration was 12.45 months.
Reported as:
Count of participants · Participants
Safety Run-In Substudy: Number of Participants Experiencing Adverse Events (AEs)
ParticipantsSafety Run-In Substudy
Participants With Any Treatment-Emergent Adverse Event (TEAE)7
Participants With a TEAE of Grade 3 or Higher5
Participants With a Serious TEAE4
PrimarySafety Run-In Substudy: Serum Concentration of Ociperlimab
Time frame:
Cycle 1 Day 1 (C1D1) Postdose (30 minutes after end of infusion), 24 and 72 Hours Postdose; C1D8; C1D15; C2D1 Predose and Postdose; C5D1 Predose; C5D1 Postdose; C5D8; C5D15; C6D1 Predose and Postdose; C9D1 Predose; C13D1 Predose; End of Treatment.
Reported as:
Geometric mean · µg/mL
Safety Run-In Substudy: Serum Concentration of Ociperlimab
µg/mLSafety Run-In Substudy
C1D1 Postdose390.76 ± 40.1
C1D1 Postdose 24 Hours278.72 ± 38.2
C1D1 Postdose 72 Hours195.49 ± 29.7
C1D8137.54 ± 49.2
C1D1588.53 ± 55.0
C2D1 Predose62.88 ± 73.2
C2D1 Postdose445.43 ± 39.8
C5D1 Predose135.30 ± 46.0
C5D1 Postdose552.30 ± 25.4
C5D8254.46 ± 28.0
C5D15179.15 ± 32.1
C6D1 Predose126.31 ± 53.1
C6D1 Postdose560.39 ± 35.6
C9D1 Predose123.00
C13D1 Predose74.40
End of Treatment44.15 ± 123.2
SecondaryProgression-free Survival (PFS) for Arm A Versus Arm B As Assessed By the Investigator

PFS is defined as the time from the date of randomization to the date of the first objectively documented tumor progression per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, or death, whichever occurs first. Median PFS was estimated using the Kaplan-Meier method. PFS was a pre-specified secondary endpoint for Arms A and B only. Progressive disease is defined as at least a 20% increase in the sum of diameters of target lesions, unequivocal progression of existing non-target lesions, or new lesions.

Time frame:
Up to 45.0 months
Reported as:
Median · months
Progression-free Survival (PFS) for Arm A Versus Arm B As Assessed By the Investigator
monthsArm A: Ociperlimab Plus TislelizumabArm B: Pembrolizumab Plus Placebo
Progression-free Survival (PFS) for Arm A Versus Arm B As Assessed By the Investigator14.3 (11.5 to 16.0)10.5 (8.4 to 12.6)
Statistical analysis
  • Arm A: Ociperlimab Plus Tislelizumab vs Arm B: Pembrolizumab Plus Placebo · Log Rank · p = 0.2792 · Hazard ratio (hr): 0.94 · 95% CI 0.77 to 1.15Stratified hazard ratio was estimated using a Cox regression model stratified by regions of enrollment (Asia versus non-Asia) and histology (squamous versus non-squamous) with Arm B as the reference group.
SecondaryProgression-free Survival (PFS) for Safety Run-In Substudy As Assessed By the Investigator

PFS is defined as the time from the date of randomization to the date of the first objectively documented tumor progression per RECIST v1.1, or death, whichever occurs first. Median PFS was estimated using the Kaplan-Meier method.

Time frame:
Up to 38.9 months
Reported as:
Median · months
Progression-free Survival (PFS) for Safety Run-In Substudy As Assessed By the Investigator
monthsSafety Run-In Substudy
Progression-free Survival (PFS) for Safety Run-In Substudy As Assessed By the Investigator6.0 (0.6 to NA)
SecondaryOverall Response Rate (ORR) for Arm A Versus Arm B As Assessed By the Investigator

ORR is defined as the percentage of participants with a documented, confirmed complete response or partial response per RECIST v1.1. ORR was a pre-specified secondary endpoint for Arms A and B only. Complete response is defined as disappearance of all target lesions, disappearance of all nontarget lesions and normalization of tumor marker level, and no new lesions. Partial response is defined as at least a 30% decrease in the sum of diameters of target lesions, no unequivocal progression of non-target lesions, and no new lesions.

Time frame:
Response was assessed every 9 weeks from randomization for the first 52 weeks and then every 12 weeks thereafter, up to 45.0 months
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) for Arm A Versus Arm B As Assessed By the Investigator
percentage of participantsArm A: Ociperlimab Plus TislelizumabArm B: Pembrolizumab Plus Placebo
Overall Response Rate (ORR) for Arm A Versus Arm B As Assessed By the Investigator61.0 (55.1 to 66.7)48.8 (42.9 to 54.7)
Statistical analysis
  • Arm A: Ociperlimab Plus Tislelizumab vs Arm B: Pembrolizumab Plus Placebo · Cochran-Mantel-Haenszel · p = 0.0032 · Odds ratio (or): 1.65 · 95% CI 1.18 to 2.30
SecondaryOverall Response Rate (ORR) for Safety Run-In Substudy As Assessed By the Investigator

ORR is defined as the percentage of participants with a documented, confirmed complete response or partial response per RECIST v1.1.

Time frame:
Response was assessed every 9 weeks from randomization for the first 52 weeks and then every 12 weeks thereafter, up to 38.9 months
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) for Safety Run-In Substudy As Assessed By the Investigator
percentage of participantsSafety Run-In Substudy
Overall Response Rate (ORR) for Safety Run-In Substudy As Assessed By the Investigator28.6 (3.7 to 71.0)
SecondaryDuration Of Response (DOR) for Arm A Versus Arm B As Assessed By the Investigator

DOR is defined as the time from the first determination of an objective response per RECIST v1.1 until the first documentation of progression or death, whichever occurs first. Median DOR was estimated using the Kaplan-Meier method. DOR was a pre-specified secondary endpoint for Arms A and B only.

Time frame:
Up to 45.0 months
Reported as:
Median · months
Duration Of Response (DOR) for Arm A Versus Arm B As Assessed By the Investigator
monthsArm A: Ociperlimab Plus TislelizumabArm B: Pembrolizumab Plus Placebo
Duration Of Response (DOR) for Arm A Versus Arm B As Assessed By the Investigator18.6 (16.5 to 24.2)28.3 (16.3 to NA)
SecondaryDuration Of Response (DOR) for Safety Run-In Substudy As Assessed By the Investigator

DOR is defined as the time from the first determination of an objective response per RECIST v1.1 until the first documentation of progression or death, whichever occurs first. Median DOR was estimated using the Kaplan-Meier method.

Time frame:
Up to 38.9 months
Reported as:
Median · months
Duration Of Response (DOR) for Safety Run-In Substudy As Assessed By the Investigator
monthsSafety Run-In Substudy
Duration Of Response (DOR) for Safety Run-In Substudy As Assessed By the InvestigatorNA (4.6 to NA)
SecondaryChange From Baseline in Global Health Status (GHS)/Quality of Life (QoL), Physical Functioning, and Pain Scores: European Organization For Research And Treatment Of Cancer Quality Of Life Questionnaire Core 30 (EORTC QLQ-C30) in Arms A and B

The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical, role, emotional, cognitive, and social functioning), 1 GHS scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 = Not at all (best) and 4 = Very Much (worst) and 2 global health QoL questions answered on a 7-point scale where 1 = Very poor and 7 = Excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. Higher scores in GHS and functional scales indicate better quality of life. Lower scores in symptom scales indicate better quality of life. Included in this outcome measure were evaluation of GHS/QoL, physical functioning, and fatigue. This was a pre-specified secondary endpoint for Arms A and B only.

Time frame:
Baseline to Cycle 5 and Cycle 7, each cycle was 3 weeks
Reported as:
Mean · score on a scale
Change From Baseline in Global Health Status (GHS)/Quality of Life (QoL), Physical Functioning, and Pain Scores: European Organization For Research And Treatment Of Cancer Quality Of Life Questionnaire Core 30 (EORTC QLQ-C30) in Arms A and B
score on a scaleArm A: Ociperlimab Plus TislelizumabArm B: Pembrolizumab Plus Placebo
Global Health Status/Quality of Life at Cycle 55.09 ± 21.2504.63 ± 17.044
Global Health Status/Quality of Life at Cycle 76.67 ± 19.6995.15 ± 17.945
Physical Functioning at Cycle 52.43 ± 14.7262.18 ± 15.521
Physical Functioning at Cycle 73.06 ± 15.4423.06 ± 16.094
Fatigue at Cycle 5-4.19 ± 19.876-3.96 ± 19.043
Fatigue at Cycle 7-6.33 ± 19.570-5.24 ± 19.406
SecondaryChange From Baseline in EORTC Lung Cancer Module Quality of Life Questionnaire Lung Cancer 13 (QLQ-LC13) Index Score, Dyspnea, Coughing, Hemoptysis, Pain in Chest, Pain in Arms/Shoulders, and Peripheral Neuropathy Scores in Arms A and B

The EORTC QLQ-LC13 is the lung cancer module of the QLQ-C30 and measures lung cancer-specific disease and treatment symptoms. It includes 13 questions about specific symptoms in which participants respond based on a 4-point scale, where 1 is "not at all" and 4 is "very much". Raw scores are transformed into a 0 to 100 scale via linear transformation. The symptom index scale was calculated by taking the mean of all symptom scale scores, and ranges from 0 to 100. Lower scores indicate an improvement in symptoms. This was a pre-specified secondary endpoint for Arms A and B only.

Time frame:
Baseline to Cycle 5 and Cycle 7, each cycle was 3 weeks
Reported as:
Mean · score on a scale
Change From Baseline in EORTC Lung Cancer Module Quality of Life Questionnaire Lung Cancer 13 (QLQ-LC13) Index Score, Dyspnea, Coughing, Hemoptysis, Pain in Chest, Pain in Arms/Shoulders, and Peripheral Neuropathy Scores in Arms A and B
score on a scaleArm A: Ociperlimab Plus TislelizumabArm B: Pembrolizumab Plus Placebo
Index Score at Cycle 5-3.19 ± 8.438-2.17 ± 7.937
Index Score at Cycle 7-4.05 ± 8.971-2.91 ± 7.475
Coughing at Cycle 5-13.15 ± 26.778-10.34 ± 27.110
Coughing at Cycle 7-13.53 ± 27.890-11.87 ± 24.157
Dyspnea at Cycle 5-2.89 ± 17.376-3.07 ± 15.432
Dyspnea at Cycle 7-3.36 ± 17.674-2.49 ± 16.637
Hemoptysis at Cycle 5-5.08 ± 14.639-5.40 ± 16.601
Hemoptysis at Cycle 7-6.60 ± 17.607-3.14 ± 14.164
Pain in Chest at Cycle 5-8.37 ± 22.588-5.40 ± 19.731
Pain in Chest at Cycle 7-11.06 ± 23.130-6.81 ± 20.093
Pain in Arm or Shoulder at Cycle 5-2.24 ± 24.9110.00 ± 25.720
Pain in Arm or Shoulder at Cycle 7-4.13 ± 24.872-1.40 ± 24.858
Peripheral Neuropathy at Cycle 51.79 ± 18.0861.23 ± 15.701
Peripheral Neuropathy at Cycle 70.99 ± 17.878-1.05 ± 15.258
SecondaryChange From Baseline in European Quality of Life-5 Level- 5 Dimension (EQ-5D-5L) Visual Analog Scale in Arms A and B

The EQ-5D-5L comprises a descriptive module that includes five dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) and a Visual Analog Scale (VAS). The VAS records a participant's self-rated health on a vertical scale from 0 to 100, where 0 is 'the worst health you can imagine' and 100 is 'the best health you can imagine'. A higher score indicates better health outcomes. This was a pre-specified secondary endpoint for Arms A and B only.

Time frame:
Baseline to Cycle 5 and Cycle 7, each cycle was 3 weeks
Reported as:
Mean · score on a scale
Change From Baseline in European Quality of Life-5 Level- 5 Dimension (EQ-5D-5L) Visual Analog Scale in Arms A and B
score on a scaleArm A: Ociperlimab Plus TislelizumabArm B: Pembrolizumab Plus Placebo
VAS at Cycle 53.04 ± 15.7122.93 ± 14.696
VAS at Cycle 73.93 ± 14.6764.72 ± 14.707
SecondaryTime To Deterioration (TTD) in Arms A and B Based on QLQ-LC13 Index Score, Cough, Chest Pain, Dyspnea, Hemoptysis, Arm or Shoulder Pain, and Peripheral Neuropathy

TTD is defined as the time from randomization to the first occurrence of worsening scores of ≥ 10 points from baseline for 2 consecutive assessments or 1 assessment followed by death from any cause. TTD was estimated using the Kaplan-Meier method. TTD was a pre-specified secondary endpoint for Arms A and B only.

Time frame:
Up to 45.0 months
Reported as:
Median · months
Time To Deterioration (TTD) in Arms A and B Based on QLQ-LC13 Index Score, Cough, Chest Pain, Dyspnea, Hemoptysis, Arm or Shoulder Pain, and Peripheral Neuropathy
monthsArm A: Ociperlimab Plus TislelizumabArm B: Pembrolizumab Plus Placebo
Index ScoreNA (NA to NA)NA (NA to NA)
CoughNA (NA to NA)NA (NA to NA)
Chest PainNA (NA to NA)NA (NA to NA)
DyspneaNA (35.8 to NA)25.0 (16.6 to NA)
HemoptysisNA (NA to NA)NA (NA to NA)
Arm or Shoulder PainNA (35.8 to NA)NA (NA to NA)
Peripheral NeuropathyNA (NA to NA)NA (NA to NA)
SecondaryTime To Deterioration (TTD) in Arms A and B Based on QLQ-C30 GHS/QoL Score, Physical Functioning, and Fatigue

TTD is defined as the time from randomization to the first occurrence of worsening scores of ≥10 points from baseline for 2 consecutive assessments or 1 assessment followed by death from any cause. TTD was estimated using the Kaplan-Meier method. TTD was a pre-specified secondary endpoint for Arms A and B only.

Time frame:
Up to 45.0 months
Reported as:
Median · months
Time To Deterioration (TTD) in Arms A and B Based on QLQ-C30 GHS/QoL Score, Physical Functioning, and Fatigue
monthsArm A: Ociperlimab Plus TislelizumabArm B: Pembrolizumab Plus Placebo
GHS/QoL ScoreNA (NA to NA)NA (NA to NA)
Physical FunctioningNA (NA to NA)NA (NA to NA)
FatigueNA (NA to NA)NA (16.6 to NA)
SecondaryNumber Of Participants Experiencing Adverse Events (AEs) in Arm A

The severity of AEs was determined according to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v5.0). AEs were graded on a scale of Grade 1 to Grade 5, with Grade 1 being the least severe and Grade 5 being the most severe. An AE is defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a study drug, whether considered related to study drug or not. An SAE is any untoward medical occurrence that, at any dose resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect, was considered a significant medical AE by the investigator based on medical judgement. This was a pre-specified secondary endpoint for Arm A only.

Time frame:
From first dose of study drug up to 30 days after last dose (or 90 days for immune-mediated AEs); maximum treatment duration was 45.0 months
Reported as:
Count of participants · Participants
Number Of Participants Experiencing Adverse Events (AEs) in Arm A
ParticipantsArm A: Ociperlimab Plus Tislelizumab
Participants With Any TEAE285
Participants with a TEAE of Grade 3 or Higher180
Participants With a Serious TEAE150
SecondarySafety Run-In Substudy: Participants With Anti-Drug Antibodies
Time frame:
Up to 38.9 months
Reported as:
Count of participants · Participants
Safety Run-In Substudy: Participants With Anti-Drug Antibodies
ParticipantsSafety Run-In Substudy
Safety Run-In Substudy: Participants With Anti-Drug Antibodies0

Adverse events

Collected over Up to 45.0 months. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Ociperlimab Plus Tislelizumab130/287 (45.3%)150/286 (52.4%)277/286 (96.9%)
Arm B: Pembrolizumab Plus Placebo137/287 (47.7%)113/287 (39.4%)267/287 (93%)
Arm C: Tislelizumab Plus Placebo43/88 (48.9%)41/87 (47.1%)79/87 (90.8%)
Safety Run-In Substudy5/7 (71.4%)4/7 (57.1%)7/7 (100%)
Most frequent serious events
Showing 10 of 237
Most frequent serious events
EventArm A: Ociperlimab Plus TislelizumabArm B: Pembrolizumab Plus PlaceboArm C: Tislelizumab Plus PlaceboSafety Run-In Substudy
PneumoniaInfections and infestations21/28622/2874/871/7
Afferent loop syndromeInjury, poisoning and procedural complications0/2860/2870/871/7
Incarcerated incisional herniaInjury, poisoning and procedural complications0/2860/2870/871/7
PneumonitisRespiratory, thoracic and mediastinal disorders7/2864/2872/871/7
PemphigoidSkin and subcutaneous tissue disorders1/2860/2870/871/7
Decreased appetiteMetabolism and nutrition disorders1/2861/2874/870/7
Cerebral infarctionNervous system disorders1/2863/2873/870/7
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/2861/2873/870/7
Immune-mediated lung diseaseRespiratory, thoracic and mediastinal disorders3/2868/2871/870/7
COVID-19 pneumoniaInfections and infestations7/2864/2870/870/7
Most frequent other events
Showing 10 of 123
Most frequent other events
EventArm A: Ociperlimab Plus TislelizumabArm B: Pembrolizumab Plus PlaceboArm C: Tislelizumab Plus PlaceboSafety Run-In Substudy
PruritusSkin and subcutaneous tissue disorders83/28641/28719/873/7
DiarrhoeaGastrointestinal disorders44/28636/28716/872/7
Decreased appetiteMetabolism and nutrition disorders52/28651/28714/872/7
InsomniaPsychiatric disorders34/28623/2878/872/7
Drug eruptionSkin and subcutaneous tissue disorders6/2861/2871/872/7
AnaemiaBlood and lymphatic system disorders80/28663/28724/870/7
CoughRespiratory, thoracic and mediastinal disorders37/28649/28719/870/7
PyrexiaGeneral disorders61/28654/28714/871/7
HypothyroidismEndocrine disorders45/28644/28718/871/7
ArthralgiaMusculoskeletal and connective tissue disorders44/28635/28717/870/7

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Arm A: Ociperlimab Plus TislelizumabArm B: Pembrolizumab Plus PlaceboArm C: Tislelizumab Plus PlaceboSafety Run-In SubstudyTotal
<=18 years00000
Between 18 and 65 years125128366295
>=65 years162159521374
Age, Continuous
Age, Continuous(years)Arm A: Ociperlimab Plus TislelizumabArm B: Pembrolizumab Plus PlaceboArm C: Tislelizumab Plus PlaceboSafety Run-In SubstudyTotal
Mean65.65 ± 8.78465.38 ± 10.11466.26 ± 9.37448.00 ± 16.58365.43 ± 9.698
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: Ociperlimab Plus TislelizumabArm B: Pembrolizumab Plus PlaceboArm C: Tislelizumab Plus PlaceboSafety Run-In SubstudyTotal
Female5752213133
Male230235674536
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A: Ociperlimab Plus TislelizumabArm B: Pembrolizumab Plus PlaceboArm C: Tislelizumab Plus PlaceboSafety Run-In SubstudyTotal
Hispanic or Latino831012
Not Hispanic or Latino278282877654
Unknown or Not Reported12003
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Arm A: Ociperlimab Plus TislelizumabArm B: Pembrolizumab Plus PlaceboArm C: Tislelizumab Plus PlaceboSafety Run-In SubstudyTotal
Asian150151457353
Black or African American20002
White133133430309
Not Reported02002
Unknown10001
Other11002
Region of Enrollment
Region of Enrollment(participants)Arm A: Ociperlimab Plus TislelizumabArm B: Pembrolizumab Plus PlaceboArm C: Tislelizumab Plus PlaceboSafety Run-In SubstudyTotal
Argentina00101
United States1193023
Japan192012758
Ukraine22105
Thailand873018
Russia33006
Spain29247060
South Korea10143027
Netherlands81009
Turkey26269061
China109106240239
Taiwan44109
Brazil22105
Poland25108
Italy22004
Georgia253210067
Australia664016
France16188042
Germany460010
Mexico10001
08

Study locations

218 sites
  • Providence Medical Foundation St Jude Heritage Healthcare
    Fullerton, California 92835, United States
  • Valkyrie Clinical Trials
    Los Angeles, California 90067, United States
  • Ocala Oncology Center Pl Dba Florida Cancer Affiliates Ocala
    Ocala, Florida 34474, United States
  • Advent Health Cancer Institute
    Orlando, Florida 32804, United States
  • Goshen Center For Cancer Care
    Goshen, Indiana 46526, United States
  • Baptist Health Lexington
    Lexington, Kentucky 40503, United States
  • University Medical Center New Orleans West Jefferson Medical Center
    New Orleans, Louisiana 70112, United States
  • Metro Minnesota Community Oncology Research Consortium (Mmcorc)
    Saint Paul, Minnesota 55101, United States
  • West Penn Hospital
    Pittsburgh, Pennsylvania 15224, United States
  • Centro Medical Austral
    Buenos Aires, 1409, Argentina
  • Centro Para La Atencion Del Paciente Oncologico (Caipo)
    San Miguel de Tucumán, 4000, Argentina
  • Concord Repatriation General Hospital
    Concord, New South Wales 2139, Australia
  • Northern Cancer Institute
    St Leonards, New South Wales 2065, Australia
  • Calvary Mater Newcastle
    Waratah, New South Wales 2298, Australia
  • Pindara Private Hospital
    Benowa, Queensland 4217, Australia
  • The Prince Charles Hospital
    Chermside, Queensland 4032, Australia
  • Mater Cancer Care Centre
    South Brisbane, Queensland 4101, Australia
  • John Flynn Private Hospital
    Tugun, Queensland 4224, Australia
  • Lyell McEwin Hospital
    Elizabeth Vale, South Australia 5112, Australia
  • Ballarat Health Services
    Ballarat, Victoria 3350, Australia
  • Monash Health
    Clayton, Victoria 3168, Australia
  • Western Health Sunshine Hospital
    St Albans, Victoria 3021, Australia
  • St John of God, Murdoch
    Murdoch, Western Australia 6150, Australia
  • Instituto Dor de Pesquisa E Ensino Distrito Federal
    Brasília, 70390140, Brazil
  • Hospital Evangelico de Cachoeiro de Itapemirim
    Cachoeiro de Itapemirim, 29308-020, Brazil
  • Centro de Pesquisas Oncologicas Cepon
    Florianópolis, 88034-000, Brazil
  • Cancer Institute of Ceara
    Fortaleza, 60430-235, Brazil
  • Cepho Centro de Estudos E Pesquisas de Hematologia E Oncologia
    Santo André, 09060-650, Brazil
  • Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto
    São José do Rio Preto, 15090-000, Brazil
  • Anhui Provincial Hospital
    Hefei, Anhui 230000, China
  • The Second Hospital of Anhui Medical University
    Hefei, Anhui 230601, China
  • Beijing Chao Yang Hospital
    Beijing, Beijing Municipality 100020, China
  • Beijing Cancer Hospital
    Beijing, Beijing Municipality 100142, China
  • Peking Union Medical College Hospital
    Beijing, Beijing Municipality 100730, China
  • Beijing Chest Hospital, Capital Medical University
    Beijing, Beijing Municipality 101149, China
  • Chongqing Cancer Hospital
    Chongqing, Chongqing Municipality 400030, China
  • The First Affiliated Hospital of Army Military Medical University
    Chongqing, Chongqing Municipality 400038, China
  • Daping Hospital, Third Military Medical University
    Chongqing, Chongqing Municipality 400042, China
  • Chongqing University Three Gorges Central Hospital
    Chongqing, Chongqing Municipality 404000, China
  • Fujian Medical University Union Hospital
    Fuzhou, Fujian 350001, China
  • Fujian Cancer Hospital
    Fuzhou, Fujian 350014, China
  • The First Affiliated Hospital of Xiamen University
    Xiamen, Fujian 361003, China
  • Affiliated Cancer Hospital and Institute of Guangzhou Medical University
    Guangzhou, Guangdong 510030, China
  • Cancer Hospital of Shantou University Medical College
    Shantou, Guangdong 515031, China
  • Shenzhen Peoples Hospital
    Shenzhen, Guangdong 518020, China
  • The Peoples Hospital of Guangxi Zhuang Autonomous Region
    Nanning, Guangxi 530021, China
  • The Tumor Hospital Affiliated to Guangxi Medical University
    Nanning, Guangxi 530021, China
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150000, China
  • Henan Cancer Hospital
    Zhengzhou, Henan 450000, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450052, China
  • Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
  • Renmin Hospital of Wuhan University
    Wuhan, Hubei 430060, China
  • Hubei Cancer Hospital
    Wuhan, Hubei 430079, China
  • The Second Xiangya Hospital of Central South University
    Changsha, Hunan 410011, China
  • Hunan Cancer Hospital
    Changsha, Hunan 410013, China
  • Changzhou No Peoples Hospital, the Affiliated Hospital of Nanjing Medical University Branch Cheng
    Changzhou, Jiangsu 213003, China
  • Nanjing First Hospital
    Nanjing, Jiangsu 210009, China
  • Nanjing Chest Hospital
    Nanjing, Jiangsu 210029, China
  • The Second Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215000, China
  • The First Affiliated Hospital of Soochow University Branch Shizi
    Suzhou, Jiangsu 215006, China
  • Xuzhou Central Hospital
    Xuzhou, Jiangsu 221000, China
  • Liaoning Cancer Hospital and Institute
    Shenyang, Liaoning 110042, China
  • The First Affiliated Hospital of Xian Jiaotong University
    Xi'an, Shaanxi 710061, China
  • The Affiliated Hospital of Qingdao University Branch Laoshan
    Qingdao, Shandong 266000, China
  • Weifang Peoples Hospital
    Weifang, Shandong 261000, China
  • Yantai Yuhuangding Hospital
    Yantai, Shandong 264000, China
  • Shanghai Chest Hospital
    Shanghai, Shanghai Municipality 200030, China
  • Affiliated Zhongshan Hospital of Fudan University
    Shanghai, Shanghai Municipality 200032, China
  • Shanghai Pulmonary Hospital
    Shanghai, Shanghai Municipality 200433, China
  • Shanxi Bethune Hospital
    Taiyuan, Shanxi 030032, China
  • Sichuan Cancer Hospital and Institute
    Chengdu, Sichuan 610041, China
  • West China Hospital, Sichuan University
    Chengdu, Sichuan 610041, China
  • Affiliated Hospital of North Sichuan Medical College
    Nanchong, Sichuan 637000, China
  • Tianjin Medical University General Hospital
    Tianjin, Tianjin Municipality 300052, China
  • Tianjin Medical University Cancer Institute and Hospital
    Tianjin, Tianjin Municipality 300060, China
  • Affiliated Cancer Hospital of Xinjiang Medical University
    Ürümqi, Xinjiang 830000, China
  • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310016, China
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310022, China
  • The First Affiliated Hospital of Ningbo University
    Ningbo, Zhejiang 315010, China
  • Taizhou Hospital of Zhejiang
    Taizhou, Zhejiang 317000, China
  • The Fourth Affiliated Hospital Zhejiang University School of Medicine
    Yiwu, Zhejiang 322000, China
  • Centre Hospitalier de La Cote Basque Saint Leon Service de Pneumologie
    Bayonne, 64100, France
  • Centre de Lutte Contre Le Cancer Institut Bergonie
    Bordeaux, 33076, France
  • Hopital de La Croix Rousse
    Lyon, 69317, France
  • Hopital Louis Pradel
    Lyon, 69500, France
  • Icm Val Daurelle Oncologie Medicale
    Montpellier, 24298, France
  • Polyclinique de Gentilly
    Nancy, 54100, France
  • Hopital Cochin
    Paris, 75014, France
  • Chu Hopital Lyon Sud
    PierreBenite, 69495, France
  • Hia Begin
    Saint-Mandé, 94160, France
  • Chu de La Reunion
    Saint-Pierre, 97448, France
  • Centre de Lutte Contre Le Cancer Institut de Cancerologie de Louest Rene Gauducheau
    SaintHerblain, 44805, France
  • Chu Nantes Hopital Nord Laennec
    SaintHerblain, 44805, France
  • Chu Tours Hopital Bretonneau Service Pneumologie
    Tours, 37000, France
  • High Technology Hospital Medcenter Ltd
    Batumi, 6000, Georgia
  • Acad Fridon Todua Medical Center Ltd Research Institute of Clinical Medicine Ltd
    Tbilisi, 0112, Georgia
  • Israel Georgian Medical Research Clinic Helsicore Ltd
    Tbilisi, 0112, Georgia
  • Jsc German Hospital
    Tbilisi, 0119, Georgia
  • Institute of Clinical Oncology Ltd
    Tbilisi, 0159, Georgia
  • Jsc Evex Hospitals Tbilisi
    Tbilisi, 0159, Georgia

Showing the first 100 of 218 sites across 19 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Socinski MA, Reck M, Paz-Ares L, Nishio M, Spira AI, Yu X, Melkadze T, Zeng A, Martinez-Bueno A, Li X, Arulananda S, Zuo Y, Chica-Duque S, Dai W, Zhou J, Tan W, Lu S. AdvanTIG-302: Phase 3 Study of Ociperlimab (Anti-TIGIT) + Tislelizumab (Anti-PD-1) Versus Pembrolizumab in Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer With PD-L1 >/=50. J Thorac Oncol. 2026 Jul 14:104089. doi: 10.1016/j.jtho.2026.104089. Online ahead of print. PubMed 42448175 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — BeiGene shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeiGene shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeiGene review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · beigene.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2021 to primary completion in May 2025, 48 months.

Results were first posted in May 2026, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2021
First posted
Feb 10, 2021
StartActual
May 24, 2021
Primary completionActual
May 30, 2025
CompletionActual
Mar 18, 2026
Results first posted
May 12, 2026
Last update
May 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04746924
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Feb 10, 2021
Start date
May 24, 2021
Primary completion
May 30, 2025
Completion
Mar 18, 2026
Results posted
May 12, 2026
Last update
May 12, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tislelizumab · Ociperlimab

Start the discussion